tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Circio Secures Additional Funding to Advance RNA Technology and Cancer Vaccine

Story Highlights
Circio Secures Additional Funding to Advance RNA Technology and Cancer Vaccine

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Targovax ASA ( (GB:0RIS) ) has shared an announcement.

Circio Holding ASA has announced that it has requested Atlas to subscribe and pay for an additional tranche of convertible bonds worth NOK 4,000,000 to support its operations until June 2025. This financial move is part of an existing agreement and is expected to bolster Circio’s efforts in advancing its RNA technology and cancer vaccine development, potentially strengthening its position in the biotechnology sector.

More about Targovax ASA

Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. It has created a unique circular RNA vector expression platform, circVec, which enhances protein expression significantly compared to traditional mRNA systems. This platform is applicable in various therapeutic areas, including genetic medicine and chronic diseases. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.

Average Trading Volume: 1,369,849

Current Market Cap: NOK64.29M

See more data about 0RIS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1